Profile

Quethera Ltd

Quethera is a gene therapy company dedicated to improving the future treatment of common blinding eye diseases. The initial focus is on developing therapies to reduce progressive visual loss in glaucoma and other conditions affecting the optic nerve. Quethera is working alongside world leaders in the glaucoma field to design clinical trials capable of examining the efficacy and safety of novel therapies in patients who lose parts of their visual field at an accelerated rate (fast-progressors). The company has expertise in gene therapeutic design and development sufficient to progress its pipeline through preclinical testing and into clinical development.

On 10 August 2018, Japanese Astellas Pharma bought privately-owned biotech Quethera for $109 million, gaining access to its gene therapy focused on developing novel treatments for glaucoma and eye disorders.

Midven’s UK Innovation & Science Seed Fund (UKI2S) was the founding investor with follow-on, co-investment from Cambridge Enterprise.

Under the terms of the purchase agreement, Astellas may pay up to $109 million in aggregate consideration (upfront and contingent payments) to Quethera shareholders to acquire Quethera.  The full announcement may be found here.

Status exits

Associated Fund UK Innovation & Science Seed Fund

Sector Medical / Biotechnology

Website www.quethera.com

Associated Team Members

Relevant News

Astellas Announces Acquisition of Quethera

Acquisition furthers Astellas’ commitment to innovation in ophthalmology with addition of novel gene therapy program…

read more

Neuroprotective Therapy Company Quethera Reveals Gene Therapy Results at ARVO

  Quethera, a biopharmaceutical company developing therapies for ocular disorders, today presented strong efficacy data…

read more

Gene Therapy Company Quethera Obtains Grant From Wellcome Trust Pathfinder Award Scheme

Quethera Ltd, a privately funded gene therapy company based at the Babraham Research Campus in…

read more

Quethera Announces Seed Financing To Develop Gene Therapy Aimed At Preventing Blindness In Glaucoma Patients

Quethera, a gene therapy company developing a treatment for glaucoma that could prevent blindness, has…

read more

Blog

A Fork in the Road: Quethera’s Story

UKI2S announced in August the successful exit of its portfolio company Quethera. Acquired by Japanese…

read more

More Companies in Medical / Biotechnology